论文部分内容阅读
目的观察替考拉宁治疗肺癌合并肺部感染患者的临床疗效和安全性。方法对32例确诊为肺癌同时合并肺部感染的患者,根据细菌学检查结果或经验性应用替考拉宁治疗,疗程7~14 d,对其疗效、细菌清除率及不良反应发生率进行统计学分析。结果替考拉宁治疗肺癌合并肺部感染,有效率为84.37%,细菌清除率为88.89%,不良反应发生率为6.25%。结论替考拉宁治疗肺癌合并肺部革兰阳性菌感染疗效确切,安全性高。
Objective To observe the clinical efficacy and safety of teicoplanin in the treatment of lung cancer with pulmonary infection. Methods Twenty-two patients diagnosed as lung cancer with pulmonary infection at the same time were treated with teicoplanin according to the results of bacteriological examination or empiric treatment. The duration of treatment ranged from 7 to 14 days. The curative effect, bacterial clearance rate and incidence of adverse reactions were statistically analyzed Analysis. Results Teicoplanin treatment of lung cancer with pulmonary infection, the effective rate was 84.37%, the bacterial clearance rate was 88.89%, the incidence of adverse reactions was 6.25%. Conclusion Teicoplanin is effective and safe in treating lung cancer with gram-positive pulmonary infection.